Certainly, the financial runway is a concern, but it's not the whole story. Reaching key milestones like GBA approval or FDA discussions could be financial game-changers. They could attract partners or investors that can provide the needed funds, thereby strengthening our negotiating position.
In the biotech sector, fortunes can turn quickly; while cash is tight, pivotal moments are ahead that could change the narrative substantially.
Pancreatic Cancer in the Media, page-56
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $13.32M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $23.68K | 4.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 23118264 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5200224 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |